SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : anika research(anik) -- Ignore unavailable to you. Want to Upgrade?

To: JFD who wrote (139)7/21/1998 7:37:00 PM
From: Andreas Helke  Read Replies (2) | Respond to of 328
 
In contrast to Depotech where the future of the company is in doubt Anika would make enough money with selling Orthovisc in the european community. There the product is already approved but except for spain not yet on the market. The disappointment is that the optimistic expectations of some investors about the date of the FDA approval will not be met.

Andreas



To: JFD who wrote (139)7/21/1998 7:49:00 PM
From: chirodoc  Respond to of 328
 
<<<<Please explain why an amended application would effect the stock?

....delays always cause these kinds of sell-offs

.......i have been in since $6--i am not worried

......if you have faith in their product hold or buy more

......if you lack faith--sell

curtis


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News